FDA warns 15 companies for illegally selling various products containing cannabidiol as agency details safety concerns Violations include marketing unapproved new human and animal drugs, selling CBD products as...
WARNING LETTER VIA OVERNIGHT DELIVERY RETURN RECEIPT REQUESTED RE: 579289 July 22, 2019 Dear Joseph Lusardi: This letter is to advise you that the U.S. Food and Drug Administration...
This is a copy of the March 10th edition of our weekly Newsletter, which we have been publishing since October 2015. Friends, This week’s news that FDA Commissioner Scott...
Statement from FDA Commissioner Scott Gottlieb, M.D., on signing of the Agriculture Improvement Act and the agency’s regulation of products containing cannabis and cannabis-derived compounds December 20, 2018 Today,...
FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy June 25, 2018 The U.S. Food and Drug Administration today...
Last week, GW Pharma (NASDAQ: GWPH) scored a milestone victory, as the thirteen-member panel at the Peripheral and Central Nervous System Drugs Advisory Committee, which met on April 19th to consider...
The potentially first botanically-derived FDA-approved cannabis-based product moved closer to approval today, as an Advisory Committee discussed the safety and efficacy of Epidolex, intended to treat seizures in children...
GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex(R) (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome LONDON and CARLSBAD, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) —...
FDA warns companies marketing unproven products, derived from marijuana, that claim to treat or cure cancer November 1, 2017 As part of the U.S. Food and Drug Administration’s ongoing...
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome...
Leading National Trade Association for Industrial Hemp Products Issues Response to Joint USDA & DEA Statement of Principles on Industrial Hemp WASHINGTON, Aug. 17, 2016 /PRNewswire-USNewswire/ — The Hemp...
Confirming reports from unnamed sources published last night, Chuck Rosenberg, the Acting Administrator of the Drug Enforcement Agency (DEA), issued a harshly worded 186-page rejection of a request by former Governors...
GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress – Positive Phase 3 Epidiolex pivotal trial in Lennox-Gastaut Syndrome (LGS) – – Positive FDA pre-NDA meeting...
Most investors understand the importance of listening to quarterly conference calls, as companies will often reveal important information in either the prepared remarks or the Q&A that follows that isn’t conveyed...
Robert T. Hoban, Esq. Hoban & Feola, LLC (www.HobanandFeola.com) Guest Post – CBD: Is There a Chill in the Air (Marketplace)?* Cannabidiol (CBD), which is one of many non-psychoactive substances...
New Cannabis Ventures reported yesterday that the Food & Drug Administration (FDA) had issued 8 warning letters to marketers of hemp-derived CBD products, and the FDA actions are sending a chill...
Earlier today, the Food & Drug Administration (FDA) posted 8 warning letters issued to marketers of products containing cannabidiol (CBD). Two of the companies receiving the letters were criticized for claims...
Similar to a year ago, when the Food & Drug Administration (FDA) issued warning letters to six companies, the FDA issued several warning letters to marketers of products with cannabidiol...
